united airlines drug testing policy

Applicable Procedure Codes: 27685, 27700, 27702, 27703, 27704, 29891, 29892, 29894, 29895, 29897, 29898, 29899. Hoy me siento mucho ms confiada y segura para mi prximo trabajo! For any non federal job its at Information About CDC Testing Requirements According to the CDC, as of Sunday, June 12, 2022 air passengers entering the U.S. will no longer be required to present Do not submit protected health information using this form. Effective Date: 04.01.2022 This policy addresses electrical stimulation and electromagnetic therapy for wounds. Yes, you take a drug test before your employment starts Answered January 30, 2022 See 1 answer Describe the drug test process at American Airlines, if there is one Asked January 10, Effective Date: 01.01.2023 This policy addresses the use of intravenous iron replacement therapy with Feraheme (ferumoxytol), Injectafer (ferric carboxymaltose), and Monoferric (ferric derisomaltose) for the treatment of iron deficiency anemia (IDA) with and without chronic kidney disease (CKD). Effective Date: 08.01.2022 This policy addresses the use of specialty pharmacy medications administered by the intravitreal route for certain ophthalmologic conditions. Effective Date: 11.01.2022 This policy addresses functional endoscopic sinus surgery (FESS). Effective Date: 06.01.2022 This policy addresses pneumatic and intermittent limb compression devices. Through this commitment, we're teaming up with Clorox to redefine our cleaning and disinfection procedures and working with the experts at Cleveland Clinic to advise us on policies that prioritize your well-being. Applicable Procedure Codes: 0052U, 0308U, 0309U, 82172, 83695, 83698, 83701, 83704, 84999, 93050, 93799, 93895, 93998. Effective Date: 01.01.2023 This policy addresses catheter ablation for atrial fibrillation. Applicable Procedure Codes: 77299, A4555, E0766.E0130, E0135, E0140, E0141, E0143, E0144, E0147, E0148, E0149, E0154, E0155, E0156, E0157, E0158, E0159. Applicable Procedure Codes: J7170, J7175, J7177, J7178, J7179, J7180, J7181, J7182, J7183, J7185, J7186, J7187, J7188, J7189, J7190, J7192, J7193, J7194, J7195, J7198, J7199, J7200, J7201, J7202, J7203, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7212. Effective Date: 08.01.2022 This policy addresses the use of interleukin-5 (IL-5) antagonists, including Cinqair (reslizumab), Fasenra (benralizumab), and Nucala (mepolizumab). 5. r/flightattendants. Applicable Procedure Codes: 77299, A4555, E0766. Effective Date: 07.01.2022 This policy addresses surgical treatment for spine pain. If you fail a random drug test while working for United Airlines youre employment will be terminated. Applicable Procedure Codes: 0345T, 0483T, 0484T, 0543T, 0544T, 0545T, 0569T, 0570T, 0646T, 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368, 33369, 33370, 33418, 33419, 33477, 33999, 93799. Effective Date: 04.01.2022 This policy addresses percutaneous patent foramen ovale closure for the prevention of recurrent ischemic stroke. United has teamed up with XpresCheck on a rapid testing option available daily to travelers originating from Houston and traveling anywhere. Customers must pre-register to reserve their testing timeslot and obtain a test on the day of travel. No walk-in appointments or appointments before the day of travel will be available. Passing a drug test is not only common in the aviation industry, for most jobs it is a federal requirement. Applicable Procedure Codes: 27412, 27415, 27416, 28446, 29866, 29867, 29879, J7330, S2112. Effective Date: 01.01.2023 This policy addresses hospital outpatient facility infusion services for intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG) therapy. Email: ODAPCWebMail@dot.gov Phone: 202-366-3784 Alt Phone: 800-225-3784 Fax: 202-366-3897 If you are deaf, hard of hearing, or have a speech disability, please dial 7-1-1 to access telecommunications relay Effective Date: 11.01.2022 This policy addresses measurement of corneal hysteresis, measurement of ocular blood flow, and monitoring of intraocular pressure. Effective Date: 11.01.2022 This policy addresses varicose vein ablative and stripping procedures and ligation procedures. Applicable Procedure Codes: 93653, 93655, 93656, 93657. Applicable Procedure Codes: G0276, G0293, G0294, G2000, S9988, S9990, S9991, S9992, S9994, S9996. Applicable Procedure Code: J3245. Being under the influence of any drugs can create an unsafe environment that leads to someone making a mistake that effects the safety of the crew and passengers. Members should always consult their physician before making any decisions about medical care. Effective Date: 11.01.2022 This policy addresses intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Inicia hoy un curso y consigue nuevas oportunidades laborales. Applicable Procedure Codes: C9399, J0180, J0219, J0221, J1322, J1458, J1743, J1931, J2840, J3397, J3490, J3590. Applicable Procedure Code: 90378. Applicable Procedures Codes: 45378, 45380, 45381, 45384, 45385, G0105, G0121. Applicable Procedures Code: J1426. Effective Date: 01.01.2023 This policy addresses molecular oncology testing for cancer indications, including breast cancer, thyroid cancer, hematological cancer, lung cancer, and uveal melanoma. Below is a summary of some important changes Applicable Procedure Codes: 22510, 22511, 22512, 22513, 22514, 22515. Effective Date: 05.01.2022 This policy addresses negative pressure wound therapy. Applicable Procedures Code: J7352. Effective Date: 01.01.2023 This policy addresses the use of intravenous (IV) and subcutaneous (SC) immune globulin (IG) products. Effective Date: 09.01.2022 This policy addresses the use of Ocrevus (ocrelizumab) for the treatment of multiple sclerosis. Cursos online desarrollados por lderes de la industria. Applicable Procedure Codes: J3357, J3358. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. Effective Date: 11.01.2022 This policy addresses mastectomy or suction lipectomy for the treatment of benign gynecomastia. Effective Date: 01.01.2023 This policy addresses outpatient and inpatient habilitative services and outpatient rehabilitation services. Effective Date: 11.01.2022 This policy addresses implanted spinal drug delivery systems for the treatment of cancer-related pain, severe spasticity, and chronic non-malignant pain. Effective Date: 10.01.2021 This policy addresses computer-assisted surgical navigation for musculoskeletal procedures and the use of intra-operative kinetic balance sensor for implant stability during knee replacement arthroplasty. Applicable Procedure Codes: 17106, 17107, 17108, 17380. Effective Date: 06.01.2022 This policy addresses deep brain stimulation and responsive cortical stimulation. Effective Date: 11.01.2022 This policy addresses the use of Xolair (omalizumab) for subcutaneous use for the treatment of moderate to severe persistent asthma, chronic urticaria, and nasal polyps. Acceso 24 horas al da para que aprendas a tu propio ritmo y en espaol. Effective Date: 12.01.2021 This policy addresses percutaneous vertebroplasty and kyphoplasty for treating spinal pain. Applicable Procedure Codes: C9399, J0178, J0179, J2503, J2777, J2778, J3490, J3590, J9035. Effective Date: 10.01.2022 This policy addresses light and laser therapy, including light phototherapy, photodynamic therapy, intense pulsed light, pulsed dye laser, and laser hair removal. Effective Date: 12.01.2022 This policy addresses breast imaging, including digital mammography, magnetic resonance imaging (MRI), ultrasound, automated breast ultrasound system, computer-aided detection (CAD), computer-aided tactile breast imaging, electrical impedance scanning (EIS), magnetic resonance elastography (MRE), and molecular breast imaging. Applicable Procedure Code: J2357. Applicable Procedure Codes: 24360, 24361, 24362, 24363, 24366, 24370, 24371, 29830, 29834, 29837, 29838. Applicable Procedure Codes: 74261, 74262, 74263. Certificados con aplicaciones internacionales y validez en LinkedIn. Shelton, CT 06484. Applicable Procedure Codes: 20974, 20975, 20979, E0747, E0748, E0749, E0760. Effective Date: 12.01.2022 This policy addresses the use of Vyepti (Eptinezumab) for the treatment of chronic and episodic migraine. Applicable Procedure Codes: 0446T, 0447T, 0448T, 95249, 95250, 95251, A4211, A4226, A4238, A9274, A9276, A9277, A9278, E0784, E0787, E1399, G0308, G0309, E2102, K0553, K0554, S1030, S1031, S1034, S1035, S1036, S1037. 22556, 22558, 22585, 22586, 22590, 22595, 22600, 22610, 22612, 22614, 22630, 22632, 22633, 22634, 22800, 22802, 22804, 22808, 22810, 22812, 22818, 22819, 22830, 22840, 22841, 22842, 22843, 22844, 22845, 22846, 22847, 22848, 22849, 22850, 22852, 22853, 22854, 22855, 22859, 22867, 22868, 22869, 22870, 22899, 62380, 63001, 63003, 63005, 63011, 63012, 63015, 63016, 63017, 63020, 63030, 63035, 63040, 63042, 63043, 63044, 63045, 63046, 63047, 63048, 63050, 63051, 63052, 63053, 63055, 63056, 63057, 63064, 63066, 63075, 63076, 63077, 63078, 63081, 63082, 63085, 63086, 63087, 63088, 63090, 63091, 63101, 63102, 63103, 63170, 63172, 63173, 63185, 63190, 63191, 63197, 63200, 63250, 63251, 63252, 63265, 63266, 63267, 63268, 63270, 63271, 63272, 63275, 63277, 63280, 63282, 63285, 63286, 63287, 63290, 63300, 63301, 63302, 63303, 63304, 63305, 63306, 63307, 63308", 2023 UnitedHealthcare | All Rights Reserved, Commercial Policy Benefits Plans for Providers, Medical & Drug Policies and Coverage Determination Guidelines for UnitedHealthcare Commercial Plans, Dental Clinical Policies and Coverage Guidelines, Reimbursement Policies for UnitedHealthcare Commercial Plans, UnitedHealthcare Oxford Clinical and Administrative Policies, UnitedHealthcare West Benefit Interpretation Policies, UnitedHealthcare West Medical Management Guidelines, Sign in to the UnitedHealthcare Provider Portal, Health plans, policies, protocols and guides, The UnitedHealthcare Provider Portal resources, 01/01/2023 UnitedHealthcare Commercial Medical Policy Update Bulletin: January 2023, 11/01/2022 UnitedHealthcare Commercial Medical Policy Update Bulletin: November 2022, 12/01/2022 UnitedHealthcare Commercial Medical Policy Update Bulletin: December 2022, UnitedHealthcare Commercial Medical Policy Update Bulletin Archive, Medical Records Requirements for Pre-Service, View the services that are subject to notification/prior authorization requirements, 17-Alpha-Hydroxyprogesterone Caproate (Makena and 17P) Commercial Medical Benefit Drug Policy, Ablative Treatment for Spinal Pain Commercial Medical Policy, Abnormal Uterine Bleeding and Uterine Fibroids Commercial Medical Policy, Actemra (Tocilizumab) Injection for Intravenous Infusion Commercial Medical Benefit Drug Policy, Adakveo (Crizanlizumab-Tmca) Commercial Medical Benefit Drug Policy, Aduhelm (Aducanumab-Avwa) Commercial Medical Benefit Drug Policy, Airway Clearance Devices Commercial Medical Policy, Alpha1-Proteinase Inhibitors Commercial Medical Benefit Drug Policy, Ambulance Services Commercial Coverage Determination Guideline, Amondys 45 (Casimersen) Commercial Medical Benefit Drug Policy, Antiemetics for Oncology Commercial Medical Benefit Drug Policy, Articular Cartilage Defect Repairs Commercial Medical Policy, Assisted Administration of Clotting Factors, Coagulant Blood Products & Other Hemostatics (for Oxford Only) Commercial Medical Benefit Drug Policy, Athletic Pubalgia Surgery Commercial Medical Policy, Attended Polysomnography for Evaluation of Sleep Disorders Commercial Medical Policy, Autologous Cellular Therapy Commercial Medical Policy, Balloon Sinus Ostial Dilation Commercial Medical Policy, Bariatric Surgery Commercial Medical Policy, Beds and Mattresses Commercial Medical Policy, Benlysta (Belimumab) Commercial Medical Benefit Drug Policy, Botulinum Toxins A and B Commercial Medical Benefit Drug Policy, Breast Imaging for Screening and Diagnosing Cancer Commercial Medical Policy, Breast Reconstruction Commercial Medical Policy, Breast Reduction Surgery Commercial Medical Policy, Brineura (Cerliponase Alfa) Commercial Medical Benefit Drug Policy, Bronchial Thermoplasty Commercial Medical Policy, Brow Ptosis and Eyelid Repair Commercial Medical Policy, Buprenorphine (Probuphine & Sublocade) Commercial Medical Benefit Drug Policy, Cardiac Event Monitoring Commercial Medical Policy, Cardiovascular Disease Risk Tests Commercial Medical Policy, Carrier Testing for Genetic Diseases Commercial Medical Policy, Catheter Ablation for Atrial Fibrillation Commercial Medical Policy, Cell-Free Fetal DNA Testing Commercial Medical Policy, Chelation Therapy for Non-Overload Conditions Commercial Medical Policy, Chemotherapy Observation or Inpatient Hospitalization Commercial Medical Policy, Chromosome Microarray Testing (Non-Oncology Conditions) Commercial Medical Policy, Cimzia (Certolizumab Pegol) Commercial Medical Benefit Drug Policy, Clinical Trials Commercial Medical Policy, Clotting Factors, Coagulant Blood Products & Other Hemostatics Commercial Medical Benefit Drug Policy, Cochlear Implants Commercial Medical Policy, Cognitive Rehabilitation Commercial Medical Policy, Collagen Crosslinks and Biochemical Markers of Bone Turnover Commercial Medical Policy, Complement Inhibitors (Soliris & Ultomiris) Commercial Medical Benefit Drug Policy, Computed Tomographic Colonography Commercial Medical Policy, Computer-Assisted Surgical Navigation for Musculoskeletal Procedures Commercial Medical Policy, Computerized Dynamic Posturography Commercial Medical Policy, Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes Commercial Medical Policy, Core Decompression for Avascular Necrosis Commercial Medical Policy, Corneal Hysteresis and Intraocular Pressure Measurement Commercial Medical Policy, Cosmetic and Reconstructive Procedures Commercial Medical Policy, Crysvita (Burosumab-Twza) Commercial Medical Benefit Drug Policy, Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis Commercial Medical Policy, Deep Brain and Cortical Stimulation Commercial Medical Policy, Denosumab (Prolia & Xgeva) Commercial Medical Benefit Drug Policy, Diagnostic Dynamic Spinal Visualization and Vertebral Motion Analysis Commercial Medical Policy, Diagnostic Spinal Ultrasonography Commercial Medical Policy, Discogenic Pain Treatment Commercial Medical Policy, Durable Medical Equipment, Orthotics, Medical Supplies and Repairs/Replacements Commercial Coverage Determination Guideline, Elective Inpatient Services Commercial Utilization Review Guideline, Electric Tumor Treatment Field Therapy Commercial Medical Policy, Electrical and Ultrasound Bone Growth Stimulators Commercial Medical Policy, Electrical Bioimpedance for Cardiac Output Measurement Commercial Medical Policy, Electrical Stimulation and Electromagnetic Therapy for Wounds Commercial Medical Policy, Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation Commercial Medical Policy, Eloctate [Antihemophilic Factor (Recombinant), FC Fusion Protein] for Connecticut Lines of Business (for Oxford Only) Commercial Medical Benefit Drug Policy, Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome Commercial Medical Policy, Enjaymo (Sutimlimab-Jome) Commercial Medical Benefit Drug Policy, Enteral Nutrition Commercial Coverage Determination Guideline, Entyvio (Vedolizumab) Commercial Medical Benefit Drug Policy, Environmental Allergen Immunotherapy Commercial Medical Policy, Epidural Steroid Injections for Spinal Pain Commercial Medical Policy, Epiduroscopy, Epidural Lysis of Adhesions and Discography Commercial Medical Policy, Erythropoiesis-Stimulating Agents Commercial Medical Benefit Drug Policy, Evenity (Romosozumab-Aqqg) Commercial Medical Benefit Drug Policy, Evkeeza (Evinacumab-Dgnb) Commercial Medical Benefit Drug Policy, Exondys 51 (Eteplirsen) Commercial Medical Benefit Drug Policy, Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Wounds Commercial Medical Policy, Facet Joint and Medial Branch Block Injections for Spinal Pain Commercial Medical Policy, Fecal Calprotectin Testing Commercial Medical Policy, Functional Endoscopic Sinus Surgery (FESS) Commercial Medical Policy, Gamifant (Emapalumab-Lzsg) Commercial Medical Benefit Drug Policy, Gastrointestinal Motility Disorders, Diagnosis and Treatment Commercial Medical Policy, Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea Commercial Medical Policy, Gender Dysphoria Treatment Commercial Medical Policy, Genetic Testing for Cardiac Disease Commercial Medical Policy, Genetic Testing for Hereditary Cancer Commercial Medical Policy, Genetic Testing for Neuromuscular Disorders Commercial Medical Policy, Genitourinary Pathogen Nucleic Acid Detection Panel Testing Commercial Medical Policy, Givlaari (Givosiran) Commercial Medical Benefit Drug Policy, Glaucoma Surgical Treatments Commercial Medical Policy, Gonadotropin Releasing Hormone Analogs Commercial Medical Benefit Drug Policy, Gynecomastia Surgery Commercial Medical Policy, Habilitative Services and Outpatient Rehabilitation Therapy Commercial Coverage Determination Guideline, Hearing Aids and Devices Including Wearable, Bone-Anchored and Semi-Implantable Commercial Medical Policy, Hepatitis Screening Commercial Medical Policy, Hereditary Angioedema (HAE), Treatment and Prophylaxis Commercial Medical Benefit Drug Policy, Home Health Care Commercial Coverage Determination Guideline, Home Hemodialysis Commercial Medical Policy, Home Traction Therapy Commercial Medical Policy, Hospital Services: Observation and Inpatient Commercial Medical Policy, Hyperbaric Oxygen Therapy and Topical Oxygen Therapy Commercial Medical Policy, Ilaris (Canakinumab) Commercial Medical Benefit Drug Policy, Ilumya (Tildrakizumab-Asmn) Commercial Medical Benefit Drug Policy, Immune Globulin (IVIG and SCIG) Commercial Medical Benefit Drug Policy, Immune Globulin Site of Care Commercial Medical Policy, Implantable Beta-Emitting Microspheres for Treatment of Malignant Tumors Commercial Medical Policy, Implanted Electrical Stimulator for Spinal Cord Commercial Medical Policy, Implanted Spinal Drug Delivery Systems Commercial Medical Policy, Infertility Diagnosis, Treatment and Fertility Preservation Commercial Medical Policy, Infliximab (Avsola, Inflectra, Remicade, & Renflexis) Commercial Medical Benefit Drug Policy, Inhaled Nitric Oxide Therapy Commercial Medical Policy, Intensity-Modulated Radiation Therapy Commercial Medical Policy, Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Commercial Medical Policy, Intrauterine Fetal Surgery Commercial Medical Policy, Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease Commercial Medical Benefit Drug Policy, Intravenous Iron Replacement Therapy (Feraheme, Injectafer, & Monoferric) Commercial Medical Benefit Drug Policy, Intravitreal Corticosteroid Implants Commercial Medical Benefit Drug Policy, Ketalar (Ketamine) and Spravato (Esketamine) Commercial Medical Benefit Drug Policy, Korsuva (Difelikefalin) Commercial Medical Benefit Drug Policy, Krystexxa (Pegloticase) Commercial Medical Benefit Drug Policy, Laser Interstitial Thermal Therapy Commercial Medical Policy, Left Atrial Appendage Closure (Occlusion) Commercial Medical Policy, Lemtrada (Alemtuzumab) Commercial Medical Benefit Drug Policy, Leqvio (Inclisiran) Commercial Medical Benefit Drug Policy, Light and Laser Therapy Commercial Medical Policy, Liposuction for Lipedema Commercial Medical Policy, Lithotripsy for Salivary Stones Commercial Medical Policy, Long-Acting Injectable Antiretroviral Agents for HIV Commercial Medical Benefit Drug Policy, Lower Extremity Endovascular Procedures Commercial Medical Policy, Luxturna (Voretigene Neparvovec-Rzyl) Commercial Medical Benefit Drug Policy, Macular Degeneration Treatment Procedures Commercial Medical Policy, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scan Site of Service Commercial Utilization Review Guideline, Manipulation Under Anesthesia Commercial Medical Policy, Manipulative Therapy Commercial Medical Policy, Manual Wheelchairs Commercial Coverage Determination Guideline, Maximum Dosage and Frequency Commercial Medical Benefit Drug Policy, Mechanical Stretching Devices Commercial Medical Policy, Medical Benefit Therapeutic Equivalent Medications Excluded Drugs Commercial Medical Benefit Drug Policy, Medical Therapies for Enzyme Deficiencies Commercial Medical Benefit Drug Policy, Meniscus Implant and Allograft Commercial Medical Policy, Minimally Invasive Procedures for Gastroesophageal Reflux Disease (GERD) and Achalasia Commercial Medical Policy, Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions Commercial Medical Policy, Motorized Spinal Traction Commercial Medical Policy, Negative Pressure Wound Therapy Commercial Medical Policy, Nerve Graft to Restore Erectile Function During Radical Prostatectomy Commercial Medical Policy, Neurophysiologic Testing and Monitoring Commercial Medical Policy, Neuropsychological Testing Under the Medical Benefit Commercial Medical Policy, Noncontact Warming Therapy, Ultrasound Therapy and Fluorescence Imaging for Wounds Commercial Medical Policy, Obstetrical Ultrasound Commercial Medical Policy, Obstructive and Central Sleep Apnea Treatment Commercial Medical Policy, Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) Commercial Medical Policy, Ocrevus (Ocrelizumab) Commercial Medical Benefit Drug Policy, Off-Label/Unproven Specialty Drug Treatment Commercial Medical Benefit Drug Policy, Office Based Procedures Site of Service Commercial Utilization Review Guideline, Omnibus Codes Commercial Medical Policy, Oncology Medication Clinical Coverage Commercial Medical Benefit Drug Policy, Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors Commercial Medical Benefit Drug Policy, Orencia (Abatacept) Injection for Intravenous Infusion Commercial Medical Benefit Drug Policy, Orthognathic (Jaw) Surgery Commercial Medical Policy, Outpatient Surgical Procedures Site of Service Commercial Utilization Review Guideline, Oxlumo (Lumasiran) Commercial Medical Benefit Drug Policy, Panniculectomy and Body Contouring Procedures Commercial Medical Policy, Parsabiv (Etelcalcetide) Commercial Medical Benefit Drug Policy, Patient Lifts Commercial Medical Policy, Pectus Deformity Repair Commercial Medical Policy, Pediatric Gait Trainers and Standing Systems Commercial Medical Policy, Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia Commercial Medical Policy, Percutaneous Patent Foramen Ovale (PFO) Closure Commercial Medical Policy, Percutaneous Vertebroplasty and Kyphoplasty Commercial Medical Policy, Pharmacogenetic Testing Commercial Medical Policy, Plagiocephaly and Craniosynostosis Treatment Commercial Medical Policy, Pneumatic Compression Devices Commercial Medical Policy, Power Mobility Devices Commercial Coverage Determination Guideline, Preimplantation Genetic Testing and Related Services Commercial Medical Policy, Preventive Care Services Commercial Coverage Determination Guideline, Private Duty Nursing Services Commercial Coverage Determination Guideline, Prolotherapy and Platelet Rich Plasma Therapies Commercial Medical Policy, Prostate Surgeries and Interventions Commercial Medical Policy, Prosthetic Devices, Wigs, Specialized, Microprocessor or Myoelectric Limbs Commercial Coverage Determination Guideline, Proton Beam Radiation Therapy Commercial Medical Policy, Provider Administered Drugs Preferred Products Commercial Medical Benefit Drug Policy, Provider Administered Drugs Site of Care Commercial Medical Policy, Radiation Therapy: Fractionation, Image-Guidance, and Special Services Commercial Medical Policy, Radicava (Edaravone) Commercial Medical Benefit Drug Policy, Reblozyl (Luspatercept-Aamt) Commercial Medical Benefit Drug Policy, Repository Corticotropin Injections Commercial Medical Benefit Drug Policy, Respiratory Interleukins (Cinqair, Fasenra, & Nucala) Commercial Medical Benefit Drug Policy, Review at Launch for New to Market Medications Commercial Medical Benefit Drug Policy, Rhinoplasty and Other Nasal Surgeries Commercial Medical Policy, Rituximab (Riabni, Rituxan, Ruxience, & Truxima) Commercial Medical Benefit Drug Policy, RNA-Targeted Therapies (Amvuttra and Onpattro) Commercial Medical Benefit Drug Policy, Ryplazim (Plasminogen, Human-Tvmh) Commercial Medical Benefit Drug Policy, Sacroiliac Joint Interventions Commercial Medical Policy, Saphnelo (Anifrolumab-Fnia) Commercial Medical Benefit Drug Policy, Scenesse (Afamelanotide) Commercial Medical Benefit Drug Policy, Screening Colonoscopy Procedures Site of Service Commercial Medical Policy, Self-Administered Medications Commercial Medical Benefit Drug Policy, Sensory Integration Therapy and Auditory Integration Training Commercial Medical Policy, Simponi Aria (Golimumab) Injection for Intravenous Infusion Commercial Medical Benefit Drug Policy, Skilled Care and Custodial Care Services Commercial Coverage Determination Guideline, Skin and Soft Tissue Substitutes Commercial Medical Policy, Skyrizi (Risankizumab-Rzaa) Commercial Medical Benefit Drug Policy, Sodium Hyaluronate Commercial Medical Benefit Drug Policy, Somatostatin Analogs Commercial Medical Benefit Drug Policy, Speech Generating Devices Commercial Medical Policy, Spinal Fusion and Bone Healing Enhancement Products Commercial Medical Policy, Spinraza (Nusinersen) Commercial Medical Benefit Drug Policy, Stelara (Ustekinumab) Commercial Medical Benefit Drug Policy, Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery Commercial Medical Policy, Subcutaneous Implantable Naltrexone Pellets, Surgery of the Ankle Commercial Medical Policy, Surgery of the Elbow Commercial Medical Policy, Surgery of the Foot Commercial Medical Policy, Surgery of the Hand or Wrist Commercial Medical Policy, Surgery of the Hip Commercial Medical Policy, Surgery of the Knee Commercial Medical Policy, Surgery of the Shoulder Commercial Medical Policy, Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins Commercial Medical Policy, Surgical Treatment for Spine Pain Commercial Medical Policy, Surgical Treatment of Lymphedema Commercial Medical Policy, Sympathetic Blockade Commercial Medical Policy, Synagis (Palivizumab) Commercial Medical Benefit Drug Policy, Temporomandibular Joint Disorders Commercial Medical Policy, Tepezza (Teprotumumab-Trbw) Commercial Medical Benefit Drug Policy, Testosterone Replacement or Supplementation Therapy Commercial Medical Benefit Drug Policy, Tezspire (Tezepelumab-Ekko) Commercial Medical Benefit Drug Policy, Thermography Commercial Medical Policy, Total Artificial Disc Replacement for the Spine Commercial Medical Policy, Total Artificial Heart and Ventricular Assist Devices Commercial Medical Policy, Transcatheter Heart Valve Procedures Commercial Medical Policy, Transcranial Magnetic Stimulation Commercial Medical Policy, Transpupillary Thermotherapy Commercial Medical Policy, Trogarzo (Ibalizumab-Uiyk) Commercial Medical Benefit Drug Policy, Tysabri (Natalizumab) Commercial Medical Benefit Drug Policy, Umbilical Cord Blood Harvesting and Storage Commercial Medical Policy, Unicondylar Spacer Devices for Treatment of Pain or Disability Commercial Medical Policy, Uplizna (Inebilizumab-Cdon) Commercial Medical Benefit Drug Policy, Vaccines Commercial Medical Benefit Drug Policy, Vagus and External Trigeminal Nerve Stimulation Commercial Medical Policy, Vertebral Body Tethering for Scoliosis Commercial Medical Policy, Video Electroencephalographic (vEEG) Monitoring and Recording Commercial Medical Policy, Viltepso (Viltolarsen) Commercial Medical Benefit Drug Policy, Virtual Upper Gastrointestinal Endoscopy Commercial Medical Policy, Visual Information Processing Evaluation and Orthoptic and Vision Therapy Commercial Medical Policy, Vitamin D Testing Commercial Medical Policy, Vyepti (Eptinezumab-Jjmr) Commercial Medical Benefit Drug Policy, Vyondys 53 (Golodirsen) Commercial Medical Benefit Drug Policy, Vyvgart (Efgartigimod Alfa-Fcab) Commercial Medical Benefit Drug Policy, Wheelchair Options and Accessories Commercial Coverage Determination Guideline, Wheelchair Seating Commercial Coverage Determination Guideline, White Blood Cell Colony Stimulating Factors Commercial Medical Benefit Drug Policy, Whole Exome and Whole Genome Sequencing Commercial Medical Policy, Xiaflex (Collagenase Clostridium Histolyticum) Commercial Medical Benefit Drug Policy, Xolair (Omalizumab) Commercial Medical Benefit Drug Policy, Zolgensma (Onasemnogene Abeparvovec-Xioi) Commercial Medical Benefit Drug Policy, Zulresso (Brexanolone) Commercial Medical Benefit Drug Policy.